Return To The Previous Page
Buy a Package
Number Of Visible Items Remaining : 3 Item

Respiratory syncytial virus (RSV) prevention: Choosing between maternal vaccination and newborn immunoprophylaxis

Respiratory syncytial virus (RSV) prevention: Choosing between maternal vaccination and newborn immunoprophylaxis
Use of palivizumab for infant immunoprophylaxis in selected patients is discussed in related UpToDate content.
IM: intramuscular; RSV: respiratory syncytial virus.

* In the northern hemisphere, vaccination should occur from September through January, so that newborns are protected during RSV season, which is from October through late March or early April. RSV season in the southern hemisphere is discussed in related UpToDate content.

¶ In many settings, nirsevimab is in limited supply.

Δ In most cases, infants born to mothers vaccinated with RSVPreF during pregnancy will not be offered nirsevimab after birth. Exceptions include infants with a high-risk condition and/or were delivered <14 days after maternal vaccination.
Graphic 143263 Version 1.0

Do you want to add Medilib to your home screen?